Kidney and bladder health

02 May 2014

Statins neither good nor bad for kidneys

Statins have no effect – neither good nor bad – on kidney function, according to an American Society of Nephrology news release.


The cholesterol-lowering medications known as statins won't help people with kidney disease avoid dialysis, but the drugs do lower cholesterol in this group, researchers have found.

"Statins had no effect – neither good nor bad – on kidney function," study author Dr Richard Haynes, of the University of Oxford in England, said in an American Society of Nephrology news release.

The study included over 6000 patients with chronic kidney disease who didn't yet need dialysis, a process in which a machine does some of the kidney's blood-filtering tasks.

About 60 million people worldwide have chronic kidney disease, according to background information in the news release.

Read: Kidney disease: are you at risk?

Drugs safe to take

People in the study randomly received either the cholesterol-lowering medication Vytorin, which is a combination of simvastatin plus the drug ezetimibe, or an inactive placebo.

The researchers followed the patients for five years. The drug combination lowered LDL cholesterol – the bad type – by an average of approximately 39 milligrams per deciliter compared to the placebo. But, it didn't affect the need for dialysis or kidney transplants in the study volunteers: about 34 percent in each group needed those treatments.

The study also confirmed that the drugs are safe for people with kidney disease to take. And, the authors noted, the drug's cholesterol-lowering properties help reduce the risk of heart disease and stroke.

Results of the study were published online in the Journal of the American Society of Nephrology. The study's main funder was Merck/Schering-Plough Pharmaceuticals, which makes Vytorin.

Read more:

More Americans to be taking statins
Statins cut stroke risk

Copyright © 2016 HealthDay. All rights reserved.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.